The acquisition – which will see MSD pay $107 for each American Depository Share (ADS) in UK-headquartered Verona – is the ...

Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's ...

According to the Financial Times, MSD – known as Merck & Co in the US and Canada – is in the final stages of a $10 billion ...

Merck has struck a roughly $10 billion deal to buy Verona Pharma, bolstering its lineup as it braces for the 2028 loss of patent exclusivity for the blockbuster cancer drug Keytruda.

U.S. drugmaker Merck is nearing a deal worth about $10 billion to buy Verona Pharma, a company focused on therapies for lung ...

Merck would pay $107 per American depository share for Verona, the report said, citing three people familiar with the matter.

Verona Pharma shares jumped in premarket trading Wednesday after the Financial Times reported that Merck & Co. is nearing a $10 billion deal to buy the U.K. drugmaker.

Bicara presented Phase I/Ib data for its ficerafusp alfa, a bispecific fusion protein targeting EGFR and transforming growth ...

US pharma giant seeks to expand footprint beyond cancer treatment as its biggest product nears patent cliff ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

US drugmaker Merck is nearing a deal worth about $10 billion to buy Verona Pharma, a company focused on therapies for lung ...